Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | SOST | Q9BQB4 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | SYNJ2 | O15056 | 3/20 | 0.75 |
| ▸ | APP | P05067 | 1/20 | 0.75 |
| ▸ | XDH | P47989 | 2/20 | 0.67 |
| ▸ | IDO1 | P14902 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taxifolin SCHEMBL29390633 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL | |
| (+)-Taxifolin SCHEMBL30300501 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL | |
| (+)-Taxifolin SCHEMBL30631315 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL | |
| (+)-Taxifolin SCHEMBL29361519 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL | |
| (+)-Taxifolin SCHEMBL13241264 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL | |
| (+)-Taxifolin SCHEMBL7628142 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL | |
| (+)-Taxifolin SCHEMBL296323 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL | |
| (+)-Taxifolin SCHEMBL29368246 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL | |
| (+)-Epitaxifolin SCHEMBL31575455 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL | |
| (+)-Taxifolin SCHEMBL29367955 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023069981-A1 | USES OF TAXIFOLIN FOR RESPIRATORY HEALTH | PHYTO TECH CORP. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20230119141-A1 | USES OF TAXIFOLIN FOR RESPIRATORY HEALTH | PHYTO TECH CORP. | 2023-04-20 | — | — | US | disclosed |
| US-20220054715-A1 | Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto | UNIV EMORY (US) | 2022-02-24 | — | — | US | disclosed |
| US-11179501-B2 | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto | EMORY UNIVERSITY (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210038566-A1 | USE OF MODULATORS OF NEET PROTEINS FOR THE TREATMENT OF INFECTION | ENYO PHARMA (FR) | 2021-02-11 | — | — | US | disclosed |
| CN-105838758-B | Water-soluble phenolic derivatives for cosmetic and therapeutic applications on the skin | 利布莱根公司 | 2020-03-06 | — | — | CN | disclosed |
| US-20190224378-A1 | Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto | UNIV EMORY (US) | 2019-07-25 | — | — | US | disclosed |
| US-10292962-B2 | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | RESEARCH INSTITUTE FOR NUTRITION AND AGING CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-10286113-B2 | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto | EMORY UNIVERSITY (US) | 2019-05-14 | — | — | US | disclosed |
| US-10188617-B2 | Modulation of cellular DNA repair activity to intercept malignancy | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-01-29 | — | — | US | disclosed |
| EP-1867729-A1 | Water soluble phenolics derivatives with dermocosmetic and therapeutic applications | Libragen (FR) | 2007-12-19 | — | — | EP | disclosed |
| EP-1317437-B1 | SYNTHESIS OF 4-ALPHA-ARYLEPICATECHINS | MARS INC (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20070197804-A1 | Synthesis of 4alpha-arylepicatechins | MARS, INCORPORATED | 2007-08-23 | — | — | US | disclosed |
| US-7126014-B2 | Synthesis of epecatechin-4α, 8-epicatechin and -catechin dimers and derivatives thereof | MARS, INC. | 2006-10-24 | — | — | US | disclosed |
| US-20050014958-A1 | Synthesis of 4alpha-arylepicatechins | MARS, INCORPORATED | 2005-01-20 | — | — | US | disclosed |
| US-6720432-B2 | OXIDIZING HYDROXYL-PROTECTED BENZYLEPITCATECHIN, ADDING NUCLEOPHILIC ARYL-ORGANOMETALLIC REAGENT, AND DEOXYGENATING FORMING COMPOUNDS SUCH AS 3,5,7,3',4'-PENTA-O-BENZYL-4-HYDROXYEPICATECHIN; PROCYANIDINS | MARS INCORPORATED | 2004-04-13 | — | — | US | disclosed |
| EP-1317437-A2 | SYNTHESIS OF 4-ALPHA-ARYLEPICATECHINS | Mars Incorporated (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20030100775-A1 | Synthesis of 4alpha-arylepicatechins | MARS INCORPORATED | 2003-05-29 | — | — | US | disclosed |
| US-6476241-B1 | Synthesis of 4α-arylepicatechins | MARS INCORPORATED | 2002-11-05 | — | — | US | disclosed |
| WO-2002020506-A2 | SYNTHESIS OF 4α-ARYLEPICATECHINS | MARS, INCORPORATED (US) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10188617-B2 | Modulation of cellular DNA repair activity to intercept malignancy | BRCA1, OGG1, TOP2B | CYP3A4 1571/4885ALOX15 3440/4885MAPT 4801/4885 |
| US-10292962-B2 | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | KRAS, VHL, HKDC1 | CYP3A4 2296/4885ALOX15 4746/4885MAPT 2755/4885 |
| US-20030100775-A1 | Synthesis of 4alpha-arylepicatechins | FABP4, TEAD4, FABP7 | CYP3A4 300/4885ALOX15 4229/4885MAPT 2148/4885 |
| US-20050014958-A1 | Synthesis of 4alpha-arylepicatechins | FABP7, FABP4, TEAD4 | CYP3A4 463/4885ALOX15 4441/4885MAPT 1948/4885 |
| US-20210038566-A1 | USE OF MODULATORS OF NEET PROTEINS FOR THE TREATMENT OF INFECTION | PEBP1, ELANE, MME | CYP3A4 4854/4885ALOX15 2754/4885MAPT 3794/4885 |
| US-20190224378-A1 | Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto | BMP4, SOST, BMP2 | CYP3A4 3169/4885ALOX15 2479/4885MAPT 2401/4885 |
| US-20230119141-A1 | USES OF TAXIFOLIN FOR RESPIRATORY HEALTH | ACE2, MAVS, ACE | CYP3A4 3248/4885ALOX15 3138/4885MAPT 1241/4885 |
| US-20220054715-A1 | Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto | BMP4, SOST, BMP2 | CYP3A4 3169/4885ALOX15 2479/4885MAPT 2401/4885 |
| US-11179501-B2 | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto | BMP4, SOST, BMP2 | CYP3A4 3169/4885ALOX15 2479/4885MAPT 2401/4885 |
| US-20070197804-A1 | Synthesis of 4alpha-arylepicatechins | FABP7, FABP4, TEAD4 | CYP3A4 463/4885ALOX15 4441/4885MAPT 1948/4885 |
| US-10286113-B2 | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto | BMP4, SOST, BMP2 | CYP3A4 3169/4885ALOX15 2479/4885MAPT 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.